Bilaal.Raja
Company record

ABBV  AbbVie Inc.

Trailing twelve months to 2026-06-30, as filed 2026-08-03 and not restated since.
Healthcare

Scale

Market cap
$464.4bn
Revenue TTM
$64.4bn
Net income TTM
$6.3bn
Free cash flow
$18.2bn
Composite score
50.3
Sector rank
#21

Valuation

P / E
73.6
EV / EBITDA
18.5
EV / sales
7.1
FCF yield
3.92%
Yield vs 10-yr
-3.92pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 5.28% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
9.8%
EBITDA margin
38.4%
ROE
-106.3%
ROIC
—
Revenue growth
10.4%

Insider activity, last 90 days

Net open-market
$-8.18m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Worldwide net revenues increased 11% on a reported basis and 10% on a constant currency basis. Net revenues for Skyrizi increased 24% for the three months and 26% for the six months ended June 30, 2026 primarily driven by continued strong market share uptake as well as market growth across all indications. Net revenues for Rinvoq increased 24% for the three months and 22% for the six months ended June 30, 2026 primarily driven by continued strong market share uptake as well as market growth across all indications. …AbbVie Inc., 10-Q, period ended 2026-06-30, filed 2026-08-03

Read the full passage →